Literature DB >> 12200148

Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo.

Jean-Rémi Bertrand1, Mireille Pottier, Antoine Vekris, Paule Opolon, Andrei Maksimenko, Claude Malvy.   

Abstract

Efficiencies of a nuclease resistant antisense oligonucleotide and of siRNA both being targeted against the green fluorescent protein stably expressed in HeLa cells are compared in cell cultures and in xenografted mice. Using Cytofectin GSV to deliver both inhibitors, the siRNAs appear to be quantitatively more efficient and its effect is lasting for a longer time in cell culture. In mice, we observed an activity of siRNAs but not of antisense oligonucleotides. The absence of efficiency of antisense oligonucleotides is probably due to their lower resistance to nuclease degradation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12200148     DOI: 10.1016/s0006-291x(02)02013-2

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  86 in total

1.  Dicer-substrate siRNA inhibits tumor necrosis factor alpha secretion in Kupffer cells in vitro: in vivo targeting of Kupffer cells by siRNA-liposomes.

Authors:  Sivakamasundari Pichu; Swapna Krishnamoorthy; Bi Zhang; Yawu Jing; Andrei Shishkov; Biddanda C Ponnappa
Journal:  Pharmacol Res       Date:  2011-09-10       Impact factor: 7.658

Review 2.  Pharmaceutical prospects for RNA interference.

Authors:  Raymond M Schiffelers; Martin C Woodle; Puthupparampil Scaria
Journal:  Pharm Res       Date:  2004-01       Impact factor: 4.200

Review 3.  Induction of RNA interference in dendritic cells.

Authors:  Mu Li; Hua Qian; Thomas E Ichim; Wei-Wen Ge; Igor A Popov; Katarzyna Rycerz; John Neu; David White; Robert Zhong; Wei-Ping Min
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

Review 4.  Subcellular fate and off-target effects of siRNA, shRNA, and miRNA.

Authors:  Saurabh Singh; Ajit S Narang; Ram I Mahato
Journal:  Pharm Res       Date:  2011-10-28       Impact factor: 4.200

Review 5.  Technologies for controlled, local delivery of siRNA.

Authors:  Samantha M Sarett; Christopher E Nelson; Craig L Duvall
Journal:  J Control Release       Date:  2015-11-28       Impact factor: 9.776

Review 6.  RNA interference: ready to silence cancer?

Authors:  Simone Mocellin; Rodolfo Costa; Donato Nitti
Journal:  J Mol Med (Berl)       Date:  2005-11-09       Impact factor: 4.599

7.  A role for intermediate filaments in determining and maintaining the shape of nerve cells.

Authors:  Brian T Helfand; Melissa G Mendez; Jason Pugh; Claude Delsert; Robert D Goldman
Journal:  Mol Biol Cell       Date:  2003-10-31       Impact factor: 4.138

8.  New core-shell nanoparticules for the intravenous delivery of siRNA to experimental thyroid papillary carcinoma.

Authors:  Henri de Martimprey; Jean-Rémi Bertrand; Claude Malvy; Patrick Couvreur; Christine Vauthier
Journal:  Pharm Res       Date:  2010-01-20       Impact factor: 4.200

9.  Systemic siRNA-mediated gene silencing: a new approach to targeted therapy of cancer.

Authors:  Mark S Duxbury; Evan Matros; Hiromichi Ito; Michael J Zinner; Stanley W Ashley; Edward E Whang
Journal:  Ann Surg       Date:  2004-10       Impact factor: 12.969

10.  Therapeutic potential of RNA interference in pain medicine.

Authors:  Ping-Heng Tan; Lin-Cheng Yang; Ru-Rong Ji
Journal:  Open Pain J       Date:  2009-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.